Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients

European Respiratory Journal

Volumn 42, Issue 6, 2013, Pages 1614-1621

  Bolhuis, Mathieu S ^a   Van Altena, Richard ^a   Van Soolingen, Dick ^b,c   De Lange, Wiel C M ^a   Uges, Donald R A ^a   Van Der Werf, Tjip S ^a   Kosterink, Jos G W ^a,d   Alffenaar, Jan Willem C ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CAPREOMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; ETHAMBUTOL; ISONIAZID; LINEZOLID; MOXIFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN;

ADULT; AGED; ANEMIA; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; OPTIC NEURITIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; STEADY STATE; THROMBOCYTOPENIA; YOUNG ADULT;

ACETAMIDES; ADULT; AGED; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; CLARITHROMYCIN; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; OXAZOLIDINONES; P-GLYCOPROTEIN; PROSPECTIVE STUDIES; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84890102278     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00001913     Document Type: Article

References (34)

1. Migliori GB, Dara M, de Colombani P, et al. Multidrug-resistant tuberculosis in Eastern Europe: still on the increase? Eur Respir J 2012; 39: 1290-1291.
2. Jenkins HE, Plesca V, Ciobanu A, et al. Assessing spatial heterogeneity of MDR-TB in a high burden country. Eur Respir J 2013; 42: 1291-1301.
3. Skrahina A, Hurevich H, Zalutskaya A, et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 2012; 39: 1425-1431.
4. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on MDR-TB outcomes. Eur Respir J 2013; 42: 156-168.
5. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. 2011 Update. Geneva, World Health Organization, 2011.
6. Prammananan T, Chaiprasert A, Leechawengwongs M. In vitro activity of linezolid against multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant (XDR)-TB isolates. Int J Antimicrob Agents 2009; 33: 190-191.
7. Cynamon MH, Klemens SP, Sharpe CA, et al. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother 1999; 43: 1189-1191.
8. De Lorenzo S, Alffenaar JW, Sotgiu G, et al. Efficacy and safety of meropenem-clavunate added to linezolidcontaining regimens in the treatment of MDR-/XDR-TB. Eur Respir J 2013; 41: 1386-1392.
9. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012; 367: 1508-1518.
10. Migliori GB, Eker B, Richardson MD, et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 2009; 34: 387-393.
11. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 1430-1442.
12. Alffenaar JW, van Altena R, Harmelink IM, et al. Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients. Clin Pharmacokinet 2010; 49: 559-565.
13. Truffot-Pernot C, Lounis N, Grosset JH, et al. Clarithromycin is inactive against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995; 39: 2827-2828.
14. Honeybourne D, Kees F, Andrews JM, et al. The levels of clarithromycin and its 14-hydroxy metabolite in the lung. Eur Respir J 1994; 7: 1275-1280.
15. Bolhuis MS, van Altena R, Uges DR, et al. Clarithromycin significantly increases linezolid serum concentrations. Antimicrob Agents Chemother 2010; 54: 5418-5419.
16. Pfizer. Zyvoxid. Product Information. College ter Beoordeling van Geneesmiddelen/Medicines Evaluation Board. http://db.cbg-meb.nl/IB-teksten/ h26569.pdf Date last accessed: June 22, 2010. Date last updated: October 19, 2011.
17. Sandoz. Clarithromycin. Product Information. College ter Beoordeling van Geneesmiddelen/Medicines Evaluation Board, 2004. http://db.cbg-meb.nl/IB- teksten/h30789.pdf Date last accessed: June 22, 2010. Date last updated: May 23, 2011.
18. Stockley IH. General considerations and an outline survey of some basic interaction mechanisms. In: Stockley IH, ed. Stockley's Drug Interactions. 6th Edn. London, Pharmaceutical Press, 2002; pp. 1-14.
19. Islinger F, Dehghanyar P, Sauermann R, et al. The effect of food on plasma and tissue concentrations of linezolid after multiple doses. Int J Antimicrob Agents 2006; 27: 108-112.
20. Harmelink IM, Alffenaar JW, Wessels AM, et al. A rapid and simple liquid chromatography-tandem mass spectrometry method for the determination of linezolid in human serum. Eur J Hosp Pharm 2008; 14: 5-8.
21. de Velde F, Alffenaar JW, Wessels AM, et al. Simultaneous determination of clarithromycin, rifampicin and their main metabolites in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 1771-1777.
22. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176-181.
23. Anger HA, Dworkin F, Sharma S, et al. Linezolid use for treatment of multidrug-resistant and extensively drugresistant tuberculosis, New York City, 2000-06. J Antimicrob Chemother 2010; 65: 775-783.
24. Proost JH, Meijer DK. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 1992; 22: 155-163.
25. Gebhart BC, Barker BC, Markewitz BA. Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin. Pharmacotherapy 2007; 27: 476-479.
26. Egle H, Trittler R, Kümmerer K, et al. Linezolid and rifampin: drug interaction contrary to expectations? Clin Pharmacol Ther 2005; 77: 451-453.
27. Gandelman K, Zhu T, Fahmi OA, et al. Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism. J Clin Pharmacol 2011; 51: 229-236.
28. Wynalda MA, Hauer MJ, Wienkers LC. Oxidation of the novel oxazolidinone antibiotic linezolid in human liver microsomes. Drug Metab Dispos 2000; 28: 1014-1017.
29. Eberl S, Renner B, Neubert A, et al. Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies. Clin Pharmacokinet 2007; 46: 1039-1049.
30. Thiebaut F, Tsuruo T, Hamada H, et al. Cellular localization of the multidrug-resistance gene product Pglycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84: 7735-7738.
31. Vu DH, Bolhuis MS, Koster RA, et al. Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother 2012; 56: 5758-5763.
32. Loddenkemper R, Sotgiu G, Mitnick CD. Cost of tuberculosis in the era of multidrug resistance: will it become unaffordable? Eur Respir J 2012; 40: 9-11.
33. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrugresistant tuberculosis. Eur Respir J 2013; 41: 1393-1400.
34. Alsaad N, van Altena R, Pranger AD, et al. Evaluation of co-trimoxazole in treatment of multidrug-resistant tuberculosis. Eur Respir J 2013; 42: 504-512.